welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
-
Bonnies Diary Dec 07https://jtvcancersupport.com/embed/28653...
-
Eugene Gerner, PhDCEO, Cancer Prevention Pharmaceuticals ...
-
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous PolyposisDuodenal carcinomas are the leading caus...
-
Carcinoma Colon and Managementhttp://www.slideshare.net/shivkishor/car...
-
Ohio State University HospitalsPatient Resources: The Ja...
-
Researchers Aim to Find New Pathway Interactions in Colorectal CancersColorectal cancer mainly exists in peopl...
-
Ignacio Blanco, MD, PhDIgnacio Blanco practices as a cancer gen...